The Effects of Each Class of Renin–Angiotensin–Aldosterone System Blockers (Angiotensin Receptor Blockers, Angiotensin Converting Enzyme Inhibitors, Mineralocorticoid Receptor Antagonists, and Combination of Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors) for Prevention of Cardiovascular Events in Pre-dialysis and On-Dialysis Chronic Kidney Disease Patients. The gene discussed is NR3C2; the disease is chronic kidney disease.